laboratori corpor america hold lh
laboratori corp america
maintain buy rate lh believ stock ampl upsid
demonstr healthi fundament includ consist growth lab cro
segment lab busi could drive modest upsid translat
upward stock momentum stock valuat remain discount multipl
expand guidanc releas act catalyst nt relief ralli valuat
revers histor mean vs
lh report ep vs street rev beat con
y/i
lab rev lab exceed street organ volum grew
rev/req growth strong contribut revenue upsid
translat segment ebit beat vs con
cro cro segment rev fell short con ebit margin improv
bp y/i book-to-bil improv covanc report ttm
guidanc lh guid ep mid-pt slightli
con investor expect low head today guidanc releas
management project view ration conserv believ suffici
drive relief ralli boost investor confid lh outlook year
lh buy
multipl mean revers lh trade price-to-earnings discount vs
today guidanc releas ep within rang growth trajectori intact drive lh
valuat back line median price-to-earnings discount vs
guidanc enough drive share head today releas investor
concern sell-sid est high given pama expect management
conservat low earn bar lh guidanc reinstil investor
confid compani earn power translat nt relief ralli
stabil lab busi posit organ growth despit network access
chang pama headwind continu expect lh gain share
lab space grow low-singl digit especi pln gain traction
lh continu expand hospit lab space note expect see
increment acquisit hospit lab translat modest growth boost
covanc continu strong growth boost sotp math mid-
high-single-digit organ growth outlook covanc highlight healthi fundament
backlog growth improv book-to-bil drive strong yield
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
laboratori corpor america hold lh
increment multipl expans especi increas earn contribut
higher growth segment push lh sotp valuat math higher
rais pt illustr lh trade median discount vs
 appli delta current price-to-earnings roll forward
multipl out-year ep arriv pt
pleas see import disclosur inform page report
laboratori corpor america hold lh
lab segment pama-rel reimburs cut
impact end beacon lb contract
work partial off-set core organ growth
benefit recent acquisit bottom line see
core organ growth factor rate headwind
contract loss near-term
cro segment revenu op incom growth
acceler strong
top line expect launchpad gener
synergi lab cro segment could
drive acceler growth new order revenu
op incom cro segment
save project launchpad could allow margin
cro segment expand meaning
lh may abl off-set volum loss
network via better
anticip share shift within aet book busi
adopt prefer lab network pln
lab segment revenu ebitda pressur
relat pama end beacon lb
contract pressur margin especi organ
cro segment signific slowdown biotech
fund could caus book revenu growth
buy rate lh given belief
announc prefer lab network posit
catalyst stock inclus like bolster
organ growth begin
expect lh continu pursu acquisit
hospital-own lab believ modestli
boost growth yield ep upsid surpris
covanc gain market share driven data-
driven approach integr compani
core labcorp busi
percentag ebit deriv higher
growth covanc busi continu grow sotp
analysi lh point higher impli price-to-earnings
believ gradual push combin compani
quarterli earn announc acquisit
pleas see import disclosur inform page report
laboratori corpor america hold lh
pleas see import disclosur inform page report
laboratori corpor america hold lh
pleas see import disclosur inform page report
laboratori corpor america hold lh
laboratori corp america
laboratori corpor america hold lead healthcar diagnost compani provid comprehens clinic laboratori
servic labcorp diagnost end-to-end drug develop support covanc drug develop
laboratori corp america
pt deriv appli discount vs price-to-earnings ep estim risk volum shift
expect marketshar gain independ region lab less expect
pt deriv appli price-to-earnings ep estim risk market share gain independ region lab
less expect price pressur
pt ep risk util spike enrol deceler optum earn deceler polit
brian tanquilut certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
jason plagman certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
pleas see import disclosur inform page report
laboratori corpor america hold lh
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash
price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period
stock select base fundament analysi may take account factor analyst convict differenti
analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi franchis pick
includ buy rate stock number vari depend analyst recommend inclus stock ad
new opportun aris remov reason inclus chang stock met desir return longer rate
buy and/or trigger stop loss stock day volatil bottom quartil stock continu
stop loss remaind stop franchis pick intend repres recommend portfolio stock
sector base may note believ pick fall within invest style growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
deem necessari past perform financi instrument recommend report taken indic
guarante futur result price valu incom financi instrument mention report rise well
fall may affect chang econom financi polit factor financi instrument denomin currenc
investor home currenc chang exchang rate may advers affect price valu incom deriv
financi instrument describ report addit investor secur adr whose valu affect
currenc underli secur effect assum currenc risk
compani mention report
laboratori corpor america hold lh buy
rate price target histori laboratori corpor america hold lh
pleas see import disclosur inform page report
